MY205171A - Methods of treatment of hypertriglyceridemia - Google Patents
Methods of treatment of hypertriglyceridemiaInfo
- Publication number
- MY205171A MY205171A MYPI2020003113A MYPI2020003113A MY205171A MY 205171 A MY205171 A MY 205171A MY PI2020003113 A MYPI2020003113 A MY PI2020003113A MY PI2020003113 A MYPI2020003113 A MY PI2020003113A MY 205171 A MY205171 A MY 205171A
- Authority
- MY
- Malaysia
- Prior art keywords
- hypertriglyceridemia
- treatment
- methods
- subject
- pemafibrate
- Prior art date
Links
- 208000006575 hypertriglyceridemia Diseases 0.000 title abstract 2
- ZHKNLJLMDFQVHJ-RUZDIDTESA-N (2r)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid Chemical compound CC[C@H](C(O)=O)OC1=CC=CC(CN(CCCOC=2C=CC(OC)=CC=2)C=2OC3=CC=CC=C3N=2)=C1 ZHKNLJLMDFQVHJ-RUZDIDTESA-N 0.000 abstract 1
- 229950009401 pemafibrate Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609048P | 2017-12-21 | 2017-12-21 | |
| PCT/US2018/066976 WO2019126597A1 (en) | 2017-12-21 | 2018-12-20 | Methods of treatment of hypertrigl yceridemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY205171A true MY205171A (en) | 2024-10-04 |
Family
ID=66995099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020003113A MY205171A (en) | 2017-12-21 | 2018-12-20 | Methods of treatment of hypertriglyceridemia |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190224169A1 (enExample) |
| EP (1) | EP3727376A4 (enExample) |
| JP (2) | JP2021506907A (enExample) |
| CN (1) | CN111741753A (enExample) |
| AU (1) | AU2018393119B2 (enExample) |
| CA (1) | CA3085951C (enExample) |
| MY (1) | MY205171A (enExample) |
| SG (1) | SG11202005850VA (enExample) |
| WO (1) | WO2019126597A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4556006A1 (en) * | 2022-07-15 | 2025-05-21 | Kowa Company, Ltd. | Drug for lowering blood ldl cholesterol |
| WO2024167964A1 (en) * | 2023-02-08 | 2024-08-15 | Kowa Company, Ltd. | Methods of treating and preventing peripheral artery disease |
| WO2025069226A1 (ja) * | 2023-09-26 | 2025-04-03 | 興和株式会社 | ペマフィブラートを含有する医薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA009374B1 (ru) * | 2003-09-03 | 2007-12-28 | Кова Ко., Лтд. | Активирующее ppar соединение и содержащая его фармацевтическая композиция |
| TWI407955B (zh) | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| MX357446B (es) * | 2012-09-27 | 2018-07-10 | Kowa Co | Agente terapeutico para dislipidemia. |
| WO2015200580A1 (en) * | 2014-06-26 | 2015-12-30 | Cymabay Therapeutics, Inc. | Treatment of severe hypertriglyceridemia |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| ES2847168T5 (es) * | 2016-07-29 | 2024-02-20 | Kowa Co | Métodos para prevenir acontecimientos cardiovasculares en poblaciones dislipidémicas de riesgo residual |
-
2018
- 2018-12-20 CN CN201880089648.7A patent/CN111741753A/zh active Pending
- 2018-12-20 CA CA3085951A patent/CA3085951C/en active Active
- 2018-12-20 WO PCT/US2018/066976 patent/WO2019126597A1/en not_active Ceased
- 2018-12-20 JP JP2020534340A patent/JP2021506907A/ja active Pending
- 2018-12-20 SG SG11202005850VA patent/SG11202005850VA/en unknown
- 2018-12-20 AU AU2018393119A patent/AU2018393119B2/en active Active
- 2018-12-20 US US16/227,440 patent/US20190224169A1/en not_active Abandoned
- 2018-12-20 EP EP18892061.5A patent/EP3727376A4/en active Pending
- 2018-12-20 MY MYPI2020003113A patent/MY205171A/en unknown
-
2023
- 2023-11-01 JP JP2023187862A patent/JP2023181451A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3727376A4 (en) | 2021-07-21 |
| EP3727376A1 (en) | 2020-10-28 |
| CA3085951A1 (en) | 2019-06-27 |
| CN111741753A (zh) | 2020-10-02 |
| JP2021506907A (ja) | 2021-02-22 |
| AU2018393119B2 (en) | 2022-08-25 |
| WO2019126597A1 (en) | 2019-06-27 |
| SG11202005850VA (en) | 2020-07-29 |
| JP2023181451A (ja) | 2023-12-21 |
| AU2018393119A1 (en) | 2020-07-23 |
| CA3085951C (en) | 2022-10-11 |
| US20190224169A1 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2020011653A (es) | Métodos de tratamiento para el abuso de sustancias. | |
| ZA201804513B (en) | Method of treating c3 glomerulopathy | |
| MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
| MY194586A (en) | Anti-garp antibody | |
| PH12017502142A1 (en) | Tetrasubstituted aklene compounds and their use | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12018550186A1 (en) | Pharmaceutical combinations for treating cancer | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| PH12019550138A1 (en) | Pharmaceutical combinations for treating cancer | |
| PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| ZA202007615B (en) | Dosing and effect of c5a antagonist with anca-associated vasculitis | |
| MY205171A (en) | Methods of treatment of hypertriglyceridemia | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| ZA201908087B (en) | Treatment for migraine | |
| MX2019004200A (es) | Terapia de combinacion. | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| PH12019502314A1 (en) | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
| MA40574A (fr) | Traitement de maladies fibrotiques | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| HK1233917A1 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy |